Table of Contents

company-logo

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

Genscript Biotech Dividend Announcement

• Genscript Biotech announced a annually dividend of $0.00 per ordinary share which will be made payable on 2017-06-21. Ex dividend date: 2017-06-05
• Genscript Biotech's trailing twelve-month (TTM) dividend yield is -%

Genscript Biotech Dividend History

Ex-Div dateDividend amountDividend typePay date
2017-06-05$0.00annually2017-06-21

Genscript Biotech Dividend per year

Genscript Biotech Dividend Yield

Genscript Biotech current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Genscript Biotech stock? Use our calculator to estimate your expected dividend yield:

Genscript Biotech Financial Ratios

P/E ratio-16.53
PEG ratio4.46
P/B ratio2.42
ROE-13.66%
Payout ratio0.00%
Current ratio4.15
Quick ratio4.06
Cash Ratio0.75

Genscript Biotech Dividend FAQ

Does Genscript Biotech stock pay dividends?
Genscript Biotech does not currently pay dividends to its shareholders.
Has Genscript Biotech ever paid a dividend?
No, Genscript Biotech has no a history of paying dividends to its shareholders. Genscript Biotech is not known for its dividend payments.
Why doesn't Genscript Biotech pay dividends?
There are several potential reasons why Genscript Biotech would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Genscript Biotech ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Genscript Biotech has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Genscript Biotech a dividend aristocrat?
Genscript Biotech is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Genscript Biotech a dividend king?
Genscript Biotech is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Genscript Biotech a dividend stock?
No, Genscript Biotech is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Genscript Biotech stocks?
To buy Genscript Biotech you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Genscript Biotech stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.